Borenstein M, Hedges LV, Higgins JP, Rothstein HR
They feel more in control with a reversible decision
Each order of GLP-1/GIP Microdose includes three 2mL vials of GLP-1/GIP and, if clinically appropriate, an additive
Similar strategies may also be used to deplete IgA, as explored with the pre-clinical candidate BHV-1400 [434], which leverages ASGPR biology in a manner similar to BHV-1300 and could represent an alternative to the likely mechanism-of-action of ARGX-121, and to deplete IgE, as shown with lysosomal targeting chimeras coupling pH-sensitive target binding and ASGPR-mediated endolysosomal delivery to FcRn-mediated cellular transport of the potential therapeutic molecule [435]
Professional Dermatologists and Aestheticians who have many years of experience
Further studies are needed to explore the broader application, long term outcomes, and safety of GLP-1 agonists in this patient population